Impact of delayed addition of PD-1/PD-L1 inhibitors to chemotherapy on outcomes in patients with extensive-stage small cell lung cancer.

Ther Adv Med Oncol · 2025 · PMC12280550 · PMID 40697877

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

OS showed a trend favoring the delayed-IO group, though the difference was not statistically significant (24.00 vs 18.59 months, HR 0.72, 95% CI 0.51–1.01; p = 0.054, Figure 2(b) ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.